CFN Exclusive CEO Interview: Ehave Connect and the Medical Marijuana Industry

Ryan Allway

January 9th, 2018

Exclusive, News, Top News

The cannabis industry is projected to exceed $50 billion in the U.S. and $22.6 billion in Canada over the coming years. While adult-use marijuana has generated a lot of attention, medical cannabis and cannabinoid therapeutics are playing an increasingly important role in the mental health care community, where they could help treat conditions like mild traumatic brain injury (concussions) and post-traumatic stress disorder. Ehave Inc. (OTCQB: EHVVF) plans to address this growing market with a comprehensive platform to improve patient management, diagnosis, and treatment.

CFN Media recently spoke with Ehave CEO Prateek Dwivedi about the company’s recent progress and plans for the future.


New Concussions Assessment Tool

Ehave is focused on empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis, and treatment. With between 1.6 million and 3.8 million sports-related concussions each year, mild traumatic brain injury represents a major problem in both amateur and professional sports. It’s estimated that up to half of concussions go unreported where they can cause lasting damage.

The company recently launched a new baseline concussion assessment tool on its Ehave Connect platform. The test records baseline concussion symptoms using validated cognitive assessments and, via the Ehave Core Platform, provides extensive information about the athlete’s history with concussions upon repeat assessment following acute injury. The goal is to track treatment progress and help guide return-to-sport strategies.

“Mild traumatic brain injury, or concussion, is the most common type of traumatic brain injury and is part of the target group of mental and cognitive conditions that Ehave is currently focused on,” said Ehave CEO Prateek Dwivedi in a press release announcing the launch of the new tool. “Initially, we plan to focus marketing of our baseline concussion test on school boards and amateur sports leagues where the need is the greatest.”

Cannabinoid Treatment Options

The cannabis industry has demonstrated the potential to treat many mental disorders, including mild traumatic brain injury and post-traumatic stress disorder. On February 3, 2017 the company entered into an agreement with MedReleaf, a Canadian licensed producer of medical cannabis, to study the therapeutic uses of cannabis using the Ehave Connect platform. The digital intake patient platform launched in November and has already seen some early success.

“Separately, Ehave is currently exploring Ehave Connect to manage treatment plans and track patient outcomes as part of a clinical trial to evaluate medical cannabis’ potential ability to provide relief to persons suffering from post-traumatic stress disorder,” said Mr. Dwivedi. “This use of our platform may be extended to mTBI, where early research has indicated the potential utility of cannabinoids in the treatment of both acute and chronic traumatic brain injury.”

The long-term goal is to collect clinical data to create a data-rich network of patient information that has the potential to validate and legitimize the medical cannabis segment of the health care industry. Without these gold standard clinical data points, the industry has struggled to gain acceptance among mainstream doctors, even after the drug has been legalized throughout Canada and in many U.S. states.

Looking Ahead

Ehave Inc. (OTCQB: EHVVF) represents a compelling opportunity in the mental health care and cannabis industries. Over the coming years, management plans to form strategic alliances with additional licensed producers of medical cannabis and publishers of psychological assessments, as well as cultivate relationships with pharmaceutical and insurance companies that could be instrumental in deploying its technologies.

“As we ramp up our capabilities in artificial intelligence and machine learning, we begin to demonstrate the true capabilities of the Ehave platform,” said CEO Prateek Dwivedi in a recent press release. “Our platform goes beyond our best-in-class data management system to provide mental health practitioners with supplemental diagnosis data based on scoring results of multiple gold standard psychological assessments.”

For more information, visit the company’s website at

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements drafted by our in house team or provided by an affiliate., a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. received fees for producing and presenting high quality and sophisticated content on along with financial and corporate news.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit:

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer